SmartCella is a global biotech company pioneering the future of targeted therapies through delivery solutions and advanced therapy development. Founded in 2014, the company is built on globally renowned science and research from Karolinska Institutet in Sweden. SmartCella combines novel delivery platforms, such as the Extroducer® (an endovascular delivery device that enables direct injection to hard-to-reach organs and tumors), with state-of-the-art development and manufacturing of stem cell-based therapies. The company operates in two business segments: Targeted Delivery and Regenerative Medicines. The international team consists of scientists, visionary innovators, and experienced business leaders, all dedicated to shaping the future of targeted therapies and delivering life-changing treatments to patients.
Total raised: $54.2M
Investors 1
| Date | Name | Website |
| 19.06.2024 | M2 Asset M... | m2assetman... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.07.2024 | - | $54.2M | - |
Mentions in press and media 17
| Date | Title | Description |
| 10.07.2026 | First Patient Dosed in XyloCor Therapeutics’ Phase 2b EXACT-2 Trial Evaluating XC001 for the Treatment of Coronary Artery Disease | XC001 is a novel investigational therapy that previously demonstrated compelling efficacy and safety results, with disease-modifying potential, in patients with refractory angina in the EXACT-1 Phase 1/2 trial. In the global EXACT-2 trial, ... |
| 12.01.2026 | SmartCella and Catalent sign nonexclusive license agreementfor GMP iPSCs | SmartCella and Catalent sign nonexclusive license agreementfor GMP iPSCs Mon, Jan 12, 2026 13:00 CET Report this content Tullinge, Sweden, and Tampa, FL, US - SmartCella Holding AB (“SmartCella”), a global biopharma company developing and m... |
| 13.11.2025 | SmartCella appoints Professor Jan Lundberg to Scientific Advisory Board | SmartCella appoints Professor Jan Lundberg to Scientific Advisory Board Thu, Nov 13, 2025 09:00 CET Report this content SmartCella Holding AB (“SmartCella”) today announces the appointment of Professor Jan Lundberg former Global Head of R&a... |
| 11.07.2025 | First patient dosed in XyloCor Therapeutics’ Phase IIb trial using SmartCella’s Extroducer delivery platform | First patient dosed in XyloCor Therapeutics’ Phase IIb trial using SmartCella’s Extroducer delivery platform Fri, Jul 11, 2025 09:30 CET Report this content SmartCella Holding AB (“SmartCella”) today shares an update from XyloCor Therapeuti... |
| 01.07.2025 | SmartCella forms Scientific Advisory Board with leading global scientific experts | SmartCella forms Scientific Advisory Board with leading global scientific experts Tue, Jul 01, 2025 09:58 CET Report this content SmartCella Holding AB (“SmartCella”) has established a Scientific Advisory Board (SAB), chaired by Professor A... |
| 28.05.2025 | Drones and Cells: The Future of Emergency Care and Regenerative Medicine | In the realm of healthcare, innovation is the lifeblood that keeps systems alive. Two recent developments in Sweden showcase how technology is reshaping emergency care and regenerative medicine. Everdrone and Procella are at the forefront, ... |
| 26.05.2025 | Procella obtains regulatory approval to widen the scope of cell therapy manufacturing for clinical stages | Procella obtains regulatory approval to widen the scope of cell therapy manufacturing for clinical stages Mon, May 26, 2025 10:00 CET Report this content ProCella, a unit within the SmartCella Regenerative Medicines business segment, has re... |
| 11.04.2025 | SmartCella publishes its 2024 Annual Report | SmartCella publishes its 2024 Annual Report Fri, Apr 11, 2025 10:00 CET Report this content Following yesterday’s invitation to the Annual General Meeting, SmartCella Holding AB (“SmartCella”) today publishes its inaugural formal Annual Rep... |
| 13.02.2025 | SmartCella enters agreement to advance Professor Johan Ericson’s research on cell replacement therapies for Parkinson’s disease | SmartCella enters agreement to advance Professor Johan Ericson’s research on cell replacement therapies for Parkinson’s disease Thu, Feb 13, 2025 10:00 CET Report this content SmartCella Holding AB (“SmartCella”) today announces entering an... |
| 12.11.2024 | SmartCella granted new European patent for the Extroducer delivery platform | SmartCella granted new European patent for the Extroducer delivery platform Tue, Nov 12, 2024 09:00 CET Report this content SmartCella Holding AB (“SmartCella”) today announces that the European Patent Office (EPO) has granted a new Europea... |
Show more